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SUMMARY
A total of 24 patients with syphilis and HIV infection were treated from January 1997 to March 2003 at the Infectious
Dermatology Outpatient Clinic of the Evandro Chagas Clinical Research Institute, Oswaldo Cruz Foundation, Rio de Janeiro,
Brazil. The caseload consisted of 20 males (83.3%) and four females (16.7%), with a mean age of 38.04 years and mean T CD4+
count of 389.5 cells/mL. Syphilis was diagnosed as secondary in 16 (62.5%) patients, late latent in eight (33.3%), and tertiary in
one (4.2%). Manifestations of secondary syphilis were palmar and plantar erythematopapulous cutaneous lesions in nine (37.5%),
papulous exanthema in four (16.7%), patchy alopecia in 3 (12.5%) and osteochondritis in one patient (4.2%). Tertiary syphilis was
characterized by verrucous lesions. Neurosyphilis was diagnosed in four patients (16.7%), with headache as the only manifestation
in two patients. Drugs used in treatment included benzathine penicillin, ceftriaxone, erythromycin, and crystalline penicillin. Cure
was achieved in 18 patients (75%). Five patients (20.8%) were retreated, three of whom presented a history of re-exposure. This
study confirms the importance of establishing the diagnosis of neurosyphilis in patients with HIV infection, in addition to performing
follow-up on treatment for syphilis.
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INTRODUCTION
The natural history of syphilis has been modified with the advent
of HIV infection. Syphilis increases the susceptibility to HIV infection2,
and HIV infection can modify the clinical course of syphilis. A more
rapid progression from the primary chancre to the secondary and tertiary
stages, increased incidence and greater severity of neurosyphilis, and
early malign syphilis have been described in patients with HIV7,8,25,26,27,29.
Few case series reports have been published on syphilis associated
with HIV infection. The current study aims to describe the clinical,
laboratory, and therapeutic aspects of syphilis in individuals with HIV
infection.
PATIENTS AND METHODS
This study was approved by the Ethics Committee of Evandro
Chagas Clinical Research Institute (IPEC), Rio de Janeiro, Brazil and
appropriated informed consent was obtained for all participants. This
was a longitudinal, open, non-placebo-controlled study consisting of
24 patients with HIV infection and syphilis, treated at the Infectious
Dermatology Outpatient Clinic, IPEC from January 1997 to March
2003 and followed up for a minimum of two years after treatment of
syphilis. This outpatient clinic receives patients referred with HIV/
AIDS that are followed up in the IPEC cohort, as well as external
patients with suspected infectious dermatoses. During the study period,
474 HIV-infected patients were treated, and syphilis comprised 2.2%
of the 1124 dermatological diagnoses in this group.
Diagnosis of syphilis was based on the Venereal Disease Research
Laboratory test (VDRL) and fluorescent treponemal antibody-
absorption (FTA-ABS) or Treponema pallidum hemagglutination assay
(TPHA). Active infection was defined as VRDL > 1/8. Based on clinical
criteria, syphilis was classified as primary, secondary, or tertiary.
Asymptomatic patients with prior VDRL titers ≤ 1/8 and who evolved
with increasing titers in a 12-month period were classified as early
latent syphilis; individuals with more than 12 months of infection or
who had no documented VDRL in the last 12 months were classified
as late latent syphilis. All patients were submitted to a spinal tap.
Diagnosis of certainty for neurosyphilis was based on VDRL reactivity
in the cerebrospinal fluid (CSF); probable diagnosis was based on
increased protein (≥ 50 mg/dL) and/or cellularity (> 5 cells/dL).
VDRL was performed at months one, three, six, nine, 12, and 24
after the completion of treatment for syphilis. The criterion of cure
was a decline in plasma VDRL to ≤ 1/8. Patients who maintained high
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titers or who presented a two-to-fourfold increase in titers after an
initial decline during follow-up were submitted to a new spinal tap for
investigation of neurosyphilis. Cases were classified as re-infection
when there was either a history of sexual exposure without condom
use or the presence of primary chancre upon physical examination,
and as relapse when there was no history of these data.
In the case of tertiary syphilis, the persistence of a titer after 24
months of follow-up was not classified as active disease. In the
investigation of HIV infection, patients had been subjected to clinical
and laboratory evaluation with routine tests including peripheral blood
lymphocyte subpopulations and HIV-1 viral load every four months.
Data analysis included estimates obtained by means of relative
frequencies and sample descriptive statistics (mean, median, and
standard deviation).
RESULTS
Investigation of syphilis (Table 1): Of the 24 HIV+ patients, the
majority was male (83.3%) and the mean age was 38.04 years (range
27 - 60). Syphilis was diagnosed as secondary in 15 patients (62.5%),
late latent in eight (33.3%), and tertiary in one (female) patient (4.2%).
Cutaneous manifestations of secondary syphilis included predominantly
erythematopapulous lesions located principally on the trunk and palmar
and plantar regions in nine patients (37.5%), followed by disseminated
erythematopapulous infiltrative lesions observed in four patients
(16.7%) and patchy alopecia in three (12.5%). In case number 2,
manifestations of secondary syphilis included alopecia and
osteochondritis in the left proximal sternal region, diagnosed by the
presence of edema, pain, and local erythema. The patient with tertiary
syphilis presented a verrucous lesion with two years’ evolution located
on the left forearm (case 15).
In five individuals (20.8%) (cases 2, 8, 10, 15, 20) diagnosis of
neurosyphilis was established by VDRL reactivity in the CSF; and in
eight individuals (33.3%) the possibility of neurosyphilis was raised
on the basis of increased protein (cases 16 and 24), cellularity (cases
21 and 23), or both (cases 1 and 6). Headache was the only symptom
present in two patients (cases 8 and 20).
In patients with secondary and latent syphilis without neurosyphilis,
benzathine penicillin 7.2 million units IM was the drug of choice.
Erythromycin was used in one patient who presented allergy to
penicillin. Both possible and confirmed neurosyphilis were treated with
crystalline penicillin 18 to 24 million units or ceftriaxone 1 to 2 g/day
for 14 days. The patient with osteochondritis received oral prednisone
associated with the treatment for syphilis, with remission of the clinical
syndrome.
Table 1
Clinical, laboratory and treatment data of syphilis in HIV+ individuals
Case Sex Age CD4 Syphilis Liquor parameters Neurosyphilis Treatment VDRL
VDRL Cells Protein Baseline Follow-up
1 M 28 267 S.S.1 negative 16 75 P5,6 Cf7 1/128 ( -)
2 M 36 623 S.S.1 ¼ 1 60 C4 Cf7 1/32 1/8
3 M 50 528 S.S.1 negative 2 20 absent Bp8 1/128 1/2
4 M 36 549 S.S.1 negative 3 30 absent Bp8 1/32 (-)
5 M 35 501 S.S.1 negative 1 33 absent Bp8 1/512 1/2
6 M 37 365 S.S.1 negative 13 60 P5,6 Cf7 1/256 1/128
7 M 29 636 L.L.S.2 negative 5 65 P5,6 Cf7 1/32 1/16
8 F 34 10 S.S.1 1/1 12 77 C4 Cp10 1/256 1/16
9 M 45 375 S.S.1 1/1 4 25 C4 Bp8 1/256 cure
10 M 36 262 S.S.1 negative not done 163 P6 Cf7 1/4096 1/8
11 M 35 242 L.L.S.2 ngative 3 20 absent Bp8 1/64 cure
12 M 42 183 L.L.S.2 negative 3 20 absent Bp8 1/32 (-)
13 M 39 806 L.L.S.2 negative 3 26 absent Bp8 1/32 (-)
14 M 27 182 S.S1 negative 4 20 absent E9 1/64 cure
15 F 413 T.S.3 ¼ 4 76 C4 Cp10 1/512 1/128
16 F 44 27 L.L.S2 negative 2 60 P6 Cf7 1/32 1/32
17 M 32 1382 S.S.1 negative 1 60 P6 Cf7 1/512 1/32
18 F 32 824 L.L.S.2 negative 5 25 absent Bp8 1/512 cure
19 M 31 162 L.L.S2 negative 3 20 absent Bp8 1/32 (-)
20 M 40 41 S.S.1 1/1 not done not done C4 Cf7 1/512 (-)
21 M 41 404 L.L.S.2 negative 2 60 P6 Cf7 1/256 1/128
22 M 32 430 S.S.1 negative 3 34 absent Bp8 1/16 (-)
23 M 60 287 S.S.1 negative 77 5 P5 Cp10 1/1024 1/8
24 M 44 618 S.S.1 negative 4 60 P6 Cf7 1/32 1/1
Secondary syphilis1; late latent syphilis2; tertiary syphilis3; LLS; Confirmed neurosyphilis (CSF = reactiveVDRL)4; Possible neurosyphilis > 5 cells/dL5; Possible
neurosyphilis protein > 50 mg/dL6; ceftriaxone7; Benzathine penicillin8; Erythromycin9; Crystalline penicillin10
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Investigation of HIV infection: In the epidemiological
classification, 17 (70.8%) and seven (29.1%) of the patients belonged
to the homo/bisexual and heterosexual exposure categories, respectively.
The mean CD4 T lymphocyte count was 389.5 (range 10 - 1382) cells/
mm3 (Table 1) and the mean HIV viral load was 194,790 (range < 80
to 800,000) copies/mL. Twenty patients (83.3%) were using anti-
retroviral drugs according to regimens from the Brazilian Ministry of
Health guidelines. Mean time from beginning of follow-up of HIV
infection to diagnosis of syphilis was 47.5 months (range: 2 to 168
months). In four individuals (16.7%) (cases 1, 8, 10, and 15), diagnosis
of HIV infection was made after diagnosis of syphilis. We observed a
higher mean VDRL titer (median 1:1081) and lower CD4+ T
lymphocyte count (median 276.20 cells/mm3) in the patients with
confirmed neurosyphilis as compared to those without neurosyphilis
[median VDRL 1:142.67 (p < 0.00) and median CD4+ T lymphocyte
511.92 cells/mm3)(p < 0.01)].
Follow-up: At the end of 24 months of treatment for syphilis, 17
patients (70.8%) presented clinical and laboratory cure and seven patients
(29.1%) persisted with titers classified as active infection (cases 6, 7, 8,
15, 16, 17, and 21). In three of these patients there was a history of re-
infection (cases 7, 17, and 21), one of whom with palmar/plantar
erythematopapulous lesions (case 17). Seven patients were submitted to
a repeat spinal tap. Three patients presented alterations in the CSF
(increased protein in cases 7 and 17 and increased protein and cellularity
in case 21); crystalline penicillin was initiated in cases 7 and ceftriaxone
in cases 17 and 21. Two patients were treated with benzathine penicillin
(cases 6 and 16) and two (cases 8 and 15) were maintained in follow-up,
since the serum titers were declining. In case 8, the laboratory criterion
for cure occurred four years after the initial episode.
In the follow-up of patients treated for the second time,
coincidentally the two patients that presented a history of re-exposure
before the re-treatment (cases 17 and 21) presented an increase in the
post-treatment VDRL titers. These patients reported a new history of
re-exposure, and one of them presented an inoculation chancre on the
penis in addition to palmar/planter papulous lesions (case 17). The
spinal tap showed normal CSF in case 17 and increased protein in case
21, and the two patients were treated with benzathine penicillin and
ceftriaxone, respectively.
DISCUSSION
The caseload presented an increased frequency of secondary and
latent syphilis, the most common clinical presentations in the presence
of HIV infection5,27. Likewise, the presence of multiple genital ulcers
and concurrent primary and secondary stages (diagnosed in one case)
are observed more frequently in HIV+ individuals24,25. Immunological
alterations induced by HIV could account for the rapid dissemination
of treponemes from the primary lesion and the early appearance of
secondary lesions. Cutaneous manifestations were those classically
described17. However, the florid clinical picture frequently called our
attention in this series, consistent with reports by other authors in
relation to the manifestations of secondary syphilis in association with
HIV infection13. Bone alterations, although rare, can be present in
secondary syphilis, as observed in one case of osteochondritis. Sporadic
cases of cranial and ulnar osteitis have been described in HIV+
patients11,14.
Diagnosis of neurosyphilis in patients with HIV infection is still a
challenge, because VDRL sensitivity in the CSF is low, and the
increased protein and cellularity can result from the HIV infection
itself in the central nervous system22. Studies with more sensitive
techniques such as polymerase chain reaction (PCR) for the detection
of T. pallidum have demonstrated low sensitivity and a lack of
correlation between positive PCR findings in the CSF and the clinical
and serological diagnosis of syphilis9,20. Because of the greater severity
with which neurosyphilis can evolve in these individuals, cases
classified as possible neurosyphilis (alterations in CSF proteins and/
or cellularity) were treated with treponemicidal drugs that penetrate
the CSF.
Neurosyphilis was diagnosed in 20.8% of the case series or 25.0%
if we include CSF alterations. A previous study showed a prevalence
rate of 23.5% 3 for neurosyphilis in HIV-positive patients as compared
to 10.0% in HIV-negative patients16. More recent studies have confirmed
that titers greater than 1/32 are predictive of neurosyphilis, regardless
of the clinical stage of syphilis and presence or absence of HIV
infection20. Furthermore, co-infection with HIV and T. pallidum
constitutes a threefold risk when the CD4+ T lymphocyte count is
below 350 cells/mm3 (21). Except for one patient, all the others in the
current sample presented high titers as described in HIV infection10.
Neurosyphilis in patients with HIV can by asymptomatic. However,
a variety of presentations can occur. An increased frequency of
ophthalmologic alterations as well as accelerated late manifestations
of neurosyphilis have been described4,15. Two patients with confirmed
neurosyphilis presented headache without an associated meningeal
syndrome.
Penicillin is still the drug of choice for all cases of syphilis. In the
case of neurosyphilis, IV crystalline penicillin on an inpatient basis or
procaine penicillin associated with probenecid on an outpatient basis
are the drugs of choice1,30. Probenecid is not available in our clinic.
Ceftriaxone can be an alternative based on its treponemicidal activity
and penetration into the CSF, having demonstrated equivalence to
procaine penicillin in conjunction with probenicid in HIV+ individuals
with neurosyphilis19,28. In our series, crystalline penicillin was offered
as the drug of choice to all patients with neurosyphilis (both confirmed
and possible). However, the vast majority opted for ceftriaxone since
it involves a single daily dose and allows for outpatient treatment.
Although based on rather imprecise evidence, relapses (12.5%)
occurred in the patients with possible neurosyphilis and who received
ceftriaxone. In HIV infection, a 23% non-response rate to ceftriaxone
was observed in one study in patients with latent syphilis with or without
neurosyphilis6. MALONE et al.18 described an 18% relapse rate in HIV+
individuals, with half of the cases having been treated with crystalline
penicillin based on a positive VDRL in the CSF or pleocytosis. One of
the questions raised is that intravenous penicillin may be ideal for the
treatment of neurosyphilis or late syphilis, but that it may be suboptimal
for the prevention of relapses. Although the issue is controversial, some
investigators suggest adjuvant treatment with benzathine penicillin for
three weeks, which is believed to act on the slowly multiplying
microorganisms, thus avoiding relapses13. Relapses have also been
related to secondary syphilis with rash or with a positive VDRL in the
CSF, in most cases occurring after 12 months of treatment10.
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One (female) patient with a persistently high titer of VDRL after
two years of follow-up may not have represented a case of active disease,
but rather a delay in the humoral response, which can occur in HIV+
patients17.
The majority of the cases in this series were from a cohort of HIV+
patients who were under regular clinical follow-up. However, four
patients were previously ignorant of their HIV infection, thus
highlighting the importance of performing HIV serology in all patients
with syphilis. Syphilis constitutes an independent risk factor for HIV
infection, and this risk appears to result from the break in the
mucocutaneous barrier due to the presence of the genital ulcer2.
This study demonstrated the importance of both establishing the
diagnosis of neurosyphilis in patients with HIV infection as well as
continued follow-up after treatment of syphilis. However, future studies
should be conducted to standardize criteria for neurosyphilis as well
as alternative therapeutic regimens for this disease in HIV+ individuals.
Likewise, educational measures for the prevention of syphilis should
be constantly reinforced in the sexually active population, without
overlooking HIV patients under follow-up.
RESUMO
Características clínicas e evolutivas da sífilis em 24 indivíduos
HIV+ no Rio de Janeiro, Brasil
Foram tratados 24 indivíduos com sífilis e infecção pelo HIV, de
Março de 1997 a Janeiro de 2003, no ambulatório de Dermatologia
Infecciosa do Instituto de Pesquisa Clínica Evandro Chagas, Fundação
Oswaldo Cruz, Rio de Janeiro, Brasil. Foram 20 homens (83,3%) e
quatro mulheres (16,7%) com idade média de 38,04 anos e contagem
média de linfócitos T CD4 de 389,5 céls/mm3. A sífilis foi classificada
como secundária em 16 pacientes (62,5%), latente tardia em oito
(33,3%) e terciária em uma paciente (4,2%). As manifestações de sífilis
secundária foram de lesões cutâneas eritematopapulosas em regiões
palmar e plantar em nove (37,5%), exantema papuloso em quatro
(16,7%), alopecia em clareira em três (12,5%) e osteocondrite em um
paciente (4,2%). A sífilis terciária apresentou-se como lesão verrucosa.
Cinco pacientes (20,8%) apresentavam neurossífilis, sendo a cefaléia
a única manifestação presente em dois pacientes. As drogas utilizadas
foram penicilina benzatina, ceftriaxone, eritromicina e penicilina. A
cura ocorreu em 18 pacientes (75%). Seis pacientes (25%) foram
retratados, sendo que três apresentavam história de re-exposição. Este
estudo confirmou a importância de se estabelecer o diagnóstico de
neurossífilis em pacientes com infecção pelo HIV, assim como de se
realizar seguimento clínico e laboratorial após o tratamento da sífilis.
ACKNOWLEDGMENTS
We thank Suely de Carvalho Maia for their laboratory support.
REFERENCES
1. AUGENBRAUN, M.H. - Treatment of syphilis 2001: non-pregnant adults. Clin. infect.
Dis., 35(suppl. 2): S187-S190, 2002.
2. BLOCKER, M.E.; LEVINE,W.C. & ST LOUIS, M.E. - HIV prevalence in patients with
syphilis, United States. Sex. transm. Dis., 27: 53-59, 2000.
3. BORDON, J.; MARTINEZ-VAZQUEZ, C.; ALVAREZ, M. et al. - Neurosyphilis in HIV-
infected patients. Europ. J. clin. Microbiol. infect. Dis., 14: 864-869, 1995.
4. CARMO, R.A.; MOURA, A.S.; CHRISTO, P.P.; MORANDI, A.C. & OLIVEIRA, M.S.
- Syphilitic meningitis in HIV-patients with meningeal syndrome: report of two cases
and review. Braz. J. infect. Dis., 5: 280-287, 2001.
5. CDR - Recent developments in syphilis epidemiology. Communicable Diseases Reports,
13, 2003.
6. DOWELL, M.E.; ROSS, P.G.; MUSHER, D.M.; CATE, T.R. & BAUGHN, R.E. - Response
of latent syphilis or neurosyphilis to ceftriaxone therapy in persons infected with
human immunodeficiency virus. Amer. J. Med., 93: 481-488, 1992.
7. GLOVER, R.A.; PIAQUADIO, D.J; KERN, S. & COCKERELL, C.J. - An unusual
presentation of secondary syphilis in patients with human immunodeficiency virus
infection. A case report and review of the literature. Arch. Derm., 128: 530-534,
1992.
8. GOLDEN, M.R.; MARRA, C.M. & HOLMES, K.K. - Update on syphilis: resurgence of
an old problem. J. Amer. med. Ass., 290: 1510-1514, 2003.
9. GORDON, S.M.; EATON, M.E.; GEORGE, R. et al. - The response of symptomatic
neurosyphilis to high-dose intravenous penicillin G in patients with human
immunodeficiency virus infection. New Engl. J. Med., 331: 1469-1473, 1994.
10. GOUREVITCH, M.N.; SELWYN, P.A.; DAVENNY, K. et al. - Effects of HIV infection
on the serologic manifestations and response to treatment of syphilis in intravenous
drug users. Ann. intern. Med., 118: 350-355, 1993.
11. GURLAND, I.A.; KORN, L.; EDELMAN, L. & WALLACH, F. - An unusual
manifestation of acquired syphilis. Clin. infect. Dis., 32: 667-669, 2001.
12. JOHNS, D.R.; TIERNEY, M. & FELSENSTEIN, D. - Alteration in the natural history of
neurosyphilis by concurrent infection with the human immunodeficiency virus. New
Engl. J. Med., 316: 1569-1572, 1987.
13. KASSUTTO, S. & SAX, P.E. - HIV and syphilis co-infection: trends and interactions.
AIDS clin. Care, 15: 9-15, 2003.
14. KASTNER, R.J.; MALONE, J.L. & DECKER, C.F. - Syphilitic osteitis in a patient with
secondary syphilis and concurrent human immunodeficiency virus infection. Clin.
infect. Dis., 18: 250-252, 1994.
15. KATZ, D.A.; BERGER, J.R. & DUNCAN, R.C. - Neurosyphilis. A comparative study of
the effects of infection with human immunodeficiency virus. Arch. Neurol., 50:
243-249, 1993.
16. KINGHORN, G.R. - Syphilis. In: COHEN, J. & POWDERLY, W.G., ed. Infectious
diseases. London, Mosby, 2004. p. 807-816.
17. LYNN, W.A. & LIGHTMAN, S. - Syphilis and HIV: a dangerous combination. Lancet
infect. Dis., 4: 456-466, 2004.
18. MALONE, J.L.; WALLACE, M.R.; HENDRICK, B.B. et al - Syphilis and neurosyphilis
in a human immunodeficiency virus type-1 seropositive population: evidence for
frequent serologic relapse after therapy. Amer. J. Med., 99: 55-63, 1995.
19. MARRA, C.M.; BOUTIN, P.; McARTHUR, J.C. et al. - A pilot study evaluating
ceftriaxone and penicillin G as treatment agents for neurosyphilis in human
immunodeficiency virus-infected individuals. Clin. infect. Dis., 30: 540-544, 2000.
20. MARRA, C.M.; GARY, D.W.; KUYPERS, J. & JACOBSON, M.A. - Diagnosis of
neurosyphilis in patients infected with human immunodeficiency virus type 1. J.
infect. Dis., 174: 219-221, 1996.
21. MARRA, C.M.; MAXWELL, C.L.; SMITH, S.L. et al. - Cerebrospinal fluid abnormalities
in patients with syphilis: association with clinical and laboratory features. J. infect.
Dis., 189: 369-376, 2004.
GUTIERREZ-GALHARDO, M.C.; VALLE, G.F.; SÁ, F.C.S.; SCHUBACH, A.O. & VALLE, A.C.F. - Clinical characteristics and evolution of syphilis in 24 HIV+ individuals in Rio de Janeiro,
Brazil. Rev. Inst. Med. trop. S. Paulo, 47(3): 153-157, 2005.
157
22. MARSHALL, D.W.; BREY, R.L; BUTZIN, C.A. et al. - CSF changes in a longitudinal
study of 124 neurologically normal HIV-1-infected U.S. Air Force personnel. J.
Acquir. Immune Defic. Syndr., 4: 777-781, 1991.
23. ROMPALO, A.M.; JOESOEF, M.R.; O’DONNELL, J.A. et al. - Clinical manifestations
of early syphilis by HIV status and gender: results of the syphilis and HIV study.
Sex. transm. Dis., 28: 158-165, 2001.
24. ROMPALO, A.M.; LAWLOR, J.; SEAMAN, P. et al. - Modification of syphilitic genital
ulcer manifestations by coexistent HIV infection. Sex. transm. Dis., 28: 448-454,
2001.
25. SANDS, M. & MARKUS, A. - Lues maligna, or ulceronodular syphilis, in a man infected
with human immunodeficiency virus: case report and review. Clin. infect. Dis., 20:
387-390, 1995.
26. SCHOFER, H.; IMHOF, M.; THOMA-GREBER, E. et al. - Active syphilis in HIV
infection: a multicentre retrospective survey. The German AIDS Study Group
(GASG). Genitourin. Med., 72: 176-178, 1996.
27. SMITH, N.H.; MUSHER, D.M.; HUANG, D.B. et al. - Response of HIV-infected patients
with asymptomatic syphilis to intensive intramuscular therapy with ceftriaxone or
procaine penicillin. Int. J. STD AIDS, 15: 328-332, 2004.
28. TUCKER, S.C.; YATES, V.M. & THAMBAR, I.V. - Unusual skin ulceration in an HIV-
positive patient who had cutaneous syphilis and neurosyphilis. Brit. J. Derm., 136:
946-948, 1997.
29. WORKOWSKI, K.A. & LEVINE, W.C. - Sexually transmitted diseases treatment
guidelines 2002. M.M.W.R, 51 (RR06): 1-80, 2002.
Received: 3 November 2004
Accepted: 7 April 2005
